Funding every eligible patient with 42 novel cancer drugs in Sri Lanka would cost almost 300 million US dollars a year; restricting them to uses that meet a cost-effectiveness threshold would cost 6 to 13.2 million.
Published as "Wisely frugal: ensuring sustainable funding for novel cancer therapeutics through a budget impact analysis in resource-limited settings". Cancer care in Sri Lanka is mostly provided by the state health system, free at the point of delivery. The authors took median survival gains for each indication of a novel cancer drug from the literature and procurement costs from the Ministry of Health, computed cost per life year gained, and applied thresholds of one and three times GDP per capita (US$3,815 and US$11,445 per life year gained).
OnCo found no Sri Lankan national health technology assessment body for cancer drugs; this is the kind of analysis that could decide which novel drugs the free state system buys first.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/